Home Contact Center Add this

Debiopharm International S.A.

developing & financing innovative drugs

Debiopharm International SA searches, evaluates and in-licenses promising drug candidates for development. Towards the end of the development process, the products are licensed out to pharmaceutical companies for world-wide marketing and sales.

Bertrand Ducrey

Bertrand Ducrey

Chief Executive Officer, Debiopharm International S.A.

Dr Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debiopharm Research & Manufacturing SA in 1995 as Pharmaceutical Project Manager. He then spent two years at Debiopharm International SA as Innovative Formulation Manager. In 2004, he returned to Debiopharm Research & Manufacturing to head the company as Chief Executive Officer until 2011. Since 2012, Dr Ducrey heads Debiopharm International SA as CEO.

Nigel McCracken

Nigel McCracken

Vice President, Translational Medicine, Debiopharm International S.A.

Dr McCracken obtained his BSc in Biochemistry/Pharmacology from Strathclyde University, UK in 1988 and a PhD in Biochemical Toxicology from Newcastle University, UK in 1991. Following a post-doctoral position in pharmacogenetics, Dr McCracken moved into pharma, where he worked for Charles River and Abbot Laboratories within the field of DMPK. In 2005, Dr McCracken moved to Altana Pharma/Nycomed (Konstanz, DE) as Senior Director of DMPK and then in 2008 became VP of Exploratory & Translational Development. In 2010 joined Shire (Eysins, VD) to Head up Translational Medicine, with a focus on implementing modern translational concepts of drug development with the ultimate goal to bring to the market and position medicines that matter. He joined Debiopharm International SA in 2014.

Stéphane Bernard

Stéphane Bernard

Director, Project Management Office, Debiopharm International S.A.

Dr Bernard received his Ph.D. in Organic Chemistry from the University of Lyon I, France, in 1999. The next year, he completed a Post-Doctorate at The School of Pharmacy Geneva-Lausanne, Switzerland. Dr Bernard has acquired several years of experience managing an R&D group, first involved in formulation and analytics then leading and coordinating cross-functional, multidisciplinary teams of the Translational Laboratory. He joined Debiopharm International SA in 2000.

Fabien Sebille

Fabien Sebille

Director, Business Development, Licensing, Marketing & Communication, Debiopharm International S.A.

Fabien Sebille holds a Ph.D in Immunology from the University of Nantes in France and pursued his scientific training with a 3-years post-doctoral fellowship at Imperial College, London. He then joined the Technology Transfer Office of the Medical Research Council to identify, validate and negotiate access to technologies of interest to Teijin Pharmaceuticals. In 2007, Fabien was hired at the newly created competitiveness cluster Alsace Biovalley in Strasbourg to structure and implement public-private partnerships in Life Sciences as well as to develop an external Business Development service to the benefit of regional start-ups and biotechs. He also co-founded TcLand, a biotech company that brought several therapeutics to the clinic. Fabien joined Debiopharm International in 2012 to lead scouting activities in the US. From this point, he occupied various leading functions in Business Development. In 2018, Fabien became the Director Business Development, Licensing, Marketing & Communication.

Frédéric Lévy

Frédéric Lévy

Director, Head of Search & Evaluation and Scientific Innovation, Debiopharm International S.A.

Dr Lévy obtained his doctoral degree at the Karolinska Institute in Stockholm and spent several years as a postdoctoral fellow at the California Institute of Technology. He moved then to Lausanne to take a leadership position at the Ludwig Institute for Cancer Research, where he was awarded a Young Investigator Award of the Cancer Research Institute, a Professorship of the Swiss National Funds and an Associate Professorship of the University of Lausanne. He joined Debiopharm International in 2008 and has held several management positions before becoming Director, Head of Search & Evaluation and Scientific Innovation in 2018. He is also a member of the Scientific Advisory Board of Eclosion in Geneva.

Chris Freitag

Chris Freitag

Vice President, Clinical Research & Development, Debiopharm International S.A.

Dr Freitag obtained his Medical Degree from Kiel University, Germany in 1994. Following several posts in hematology/oncology, internal and respiratory medicine in the UK, Dr Freitag moved to Australia to work in emergency medicine and rural/remote practice for almost 4 years. In 2001, Dr Freitag moved to the pharmaceutical industry in Pharmacovigilance/drug Safety with Roche. After 6 years in PV and Medical Affairs, he joined Shire in the UK as Director of Clinical Medicine. At Shire, he held several positions in clinical development and medical affairs, covering the internal medicine portfolio, finally as VP, Global Clinical development and Innovation. In 2014 he joined BTG plc in the UK as SVP to Head up Vascular Medicine and went on to lead global clinical development across the portfolio in oncology, respiratory medicine, interventional vascular medicine and specialty pharmaceuticals/antidote products. He joined Debiopharm International SA in 2016.

Vanessa Currat

Vanessa Currat

General Counsel, Director IP and Legal Affairs, Debiopharm International S.A.

Vanessa Currat holds a Master of Business Law ("DESS") from the University of Paris V - René Descartes and a Master of International Economical Law from Paris I – La Sorbonne ("DEA"). She has more than 20 years of management experience in the biopharma industry with particular expertise in: negotiation of licensing and acquisition deals, Intellectual Property management including strategy conception and implementation, risk management, competition, corporate and labor law. She also has a successful track record in handling worldwide commercial and patent litigations. Prior responsibilities include positions at Kimbrough & Associates, Alcatel-Lucent, Vetrotech, and Debiotech. She joined Debiopharm International SA in 1996 where she served as lawyer and IP Counsel, becoming IP Manager in 2000. Since implementing the merge of the IP and Legal Services departments in 2006, she has been the head of Legal Affairs of Debiopharm Group. She joined the Executive Committee in 2014.

Houssam Ibrahim

Houssam Ibrahim

Vice President Pharmaceutical Development, Debiopharm International S.A.

Dr Ibrahim received his Diploma of Pharmacy from the Faculty of Sciences of the University of Geneva, Switzerland in 1983, and in 1989, obtained his Ph.D. in Sciences from the ‘Laboratoire de Pharmacie Galénique’, University of Geneva. Dr Ibrahim has acquired international experience in the pharmaceutical industry, including quality assurance, regulatory affairs, pharmaceutical sciences and GMP productions for clinical trial materials and commercial products. Previous job experiences include work in Quality Assurance and Regulatory Affairs at Serono. He joined Debiopharm International SA in 1992.

Peggy Lipp

Peggy Lipp

Director, Regulatory Affairs, Business Intelligence & Market Access, Debiopharm International S.A.

Mrs Lipp received her M.Sc. (Dipl. Ing.) degree in Biotechonology from Technical university of Graz in Austria and is experienced in leading the development of global regulatory strategies in a broad number of therapeutic areas for both early and late stage products. Before joining Debiopharm, Ms. Lipp was Director of Regulatory Affairs in Janssen, where she was directly responsible for successful key product approvals across multiple therapeutic areas. Prior to joining Janssen, she held multiple regulatory and research positions with increasing responsibilities in Biogen, Baxter, ApoPharma, and Mount Sinai School of Medicine. She joined Debiopharm in 2015 to lead Regulatory Affairs, Market Access and Business Intelligence teams.

Manuela Perraudin

Manuela Perraudin

Director, Human Resources, Debiopharm International S.A.

Mrs Perraudin obtained a Degree in International Relations from the Graduate Institute of International Studies in 1992 and a Master of Business Administration from the IMD, in 2002. With 21 years’ experience in Human Resources, she has held several senior management positions in the medical technology, hi-tech and engineering industries. She spent seven years at Medtronic Europe as Human Resources Director of the European Cardiovascular Division, subsequently held the position of Corporate Vice President Human Resources at Advanced Digital Broadcast and then became the Global Division Vice President Human Resources at IMI Hydronics, an organization including 6 manufacturing sites and 2000 employees in Europe, Asia and America. She joined Debiopharm International in 2014.

Alexandre Maret

Alexandre Maret

Director Finance and Administration - Debiopharm International S.A.

Mr Maret received his Enterprise Economist diploma from the University of Applied Sciences, Western Switzerland (HES SO)  in 1996. He has acquired an extensive experience in the accounting services of several companies (bank, international fiduciary, e-business). He joined Debiopharm International SA in 2005.

Against the background of the vision and of the mission of Debiopharm International, the Strategic Committee helps the shareholders and leadership of the company to anticipate, identify and understand the upcoming trends as well as to adapt in a timely and realistic manner to the key features of tomorrow's pharmaceutical industry.

Thierry Mauvernay

President Debiopharm Group

Mr Mauvernay received his Master of Science in Economics in 1975. He then obtained a degree (MBA) from the 'Institut d'Administration des Entreprises’ and a DESS in Marketing (Master II Degree) in Clermont-Ferrand, France in 1976. In 1978, he founded an international cosmetics company, which he later sold but continued to manage until July 2001, when he joined Debiopharm SA as Executive Vice President with direct responsibilities for the Finance and Administration Department. In 2006, Mr Mauvernay handed over his operational activities within Debiopharm SA and has since been focusing on the administration, finance and strategy of Debiopharm Group. Since 2012 he is Delegate of the Board of Debiopharm Group.

Bertrand Ducrey

Chief Executive Officer, Debiopharm International SA

Dr Ducrey received his Diploma of Pharmacy from the School of Pharmacy of Lausanne University, Switzerland in 1990 and then obtained his Ph.D. in Pharmaceutical Sciences in 1995. He joined Debio R.P. in 1995 as Pharmaceutical Project Manager. He spent two years at Debiopharm S.A. as Innovative Formulation Manager. In 2004, he returned to Debio R.P. S.A. to head the company as Chief Executive Officer. Since 2012, Dr Ducrey heads Debiopharm International SA as CEO.

Nicolas Py

General Secretary

Nicolas Py received his Master’s degree in Cellular Biology and Molecular Genetics from the universities of Versailles and Paris-Sud in 1997, then graduated as an Engineer in Life Sciences and Applied Biochemistry from AgroParisTech Institute in 2000, and completed his education with a Master’s degree in Marketing and Management from EM Strasbourg Business School in 2003. He started his career in 2000 as an analyst at ADIT, a consulting company specialized in Competitive Intelligence (Paris and Strasbourg, France). In 2003, he joined the Business Development department of Transgene (Strasbourg, France), a listed biopharmaceutical company focused on developing targeted immunotherapies. From 2004 to 2007, he worked as Competitive Intelligence analyst at Air Liquide Group (Paris, France), the world leader in gases, technologies and services for industry and health. He joined Debiopharm in 2007 and he is now Director, Head of Market Intelligence.

Michele Antonnelli

Michele Antonelli

Member

Michele Antonelli has a master degree in Plant Biology from the University of Bari, Italy. He qualified the ENI’s (Italian National Oil Company) postgraduate programme in Biotechnology and Advanced Genetics at the Catholic University in Piacenza, Italy and at the Iowa State University Ames, Iowa, USA. From 1982 to 1992, he worked at Enichem, Italy as Research fellow and then as Head of Molecular and Cell Biology Unit. In 1992, he joined Serono in Geneva, Switzerland, where he held several senior managerial positions in Quality, Product and Process Development and Industrial Manufacturing in Biotechnology, and as Senior Vice President Biotech Manufacturing and Process Development. In 2008, Mr. Antonelli joined UCB as Executive Vice President Technical Operations & Quality Assurance. In 2012 he joined the European Commercial Operations team as Executive Vice President & Managing Director of UCB France. In November 2015 he joint Stallergenes SAS as the Executive Vice President, Head of International Operations. Since February 2016, Mr. Antonelli is the President of Stallergenes SAS and Executive Vice President, Head of Europe & Rest of World.

Jean-Luc Belingard

Jean-Luc Bélingard

Member

Mr. Belingard graduated from ‘Ecole des Hautes Etudes Commerciales (HEC) Paris (1971), and he holds a Master of Business Administration (MBA) from Cornell University, USA (1974). Since then, Mr. Belingard has held many management positions at Merck, Sharp and Dohme (Sales and Marketing Director, 1974-1981, Senior Director, Promotion Planning, 1981-1983), Roche France (“President du Directoire”, 1983-1990), F. Hoffman-La Roche Ltd. (Member of the Executive Committee, 1990-1998), Roche Diagnostics, Basel (Chief Executive Officer, 1990-1998), bioMerieux-Pierre Fabre (Chief Executive Officer, 1999-2001), Ipsen Group (Chairman and Chief Executive Officer, 2002-2010). In January 2011, Mr. Belingard was appointed Chairman and Chief Executive Officer of bioMérieux.

  

François Crémieux

François Crémieux

Member

François Crémieux received his Master’s degree from Paris-Dauphine and Lancaster (UK) universities in 1994. He then received a Master degree in public health from Paris Diderot Medical School and graduated in hospital management from the French school of public health (EHESP). After working for the United-Nations and the World Health Organization in different post conflict environments including as CEO of the hospital in Mitrovica (Kosovo), Mr. Crémieux's career had been focused on hospital management in France. He was the Director of the Hotel-Dieu hospital in Paris from 2008 to 2010. He then became the director of hospitals and clinics for the Greater Paris health authority overseeing over 70 separate institutions from 2010 to 2012 before joining the cabinet of the French Minister for Social Affairs and Health from 2012 to 2014. Since 2014, Mr. Crémieux has been the CEO of the northern Paris University hospitals. Mr. Crémieux is a member of the committee as an expert on behalf of the Greater Paris University Hospitals (AP-HP). He receives no personal compensation for his contributions to the committee.

Debiopharm International S.A.

Forum "après-demain"
Chemin Messidor 5-7
Case postale 5911
1002 Lausanne
Switzerland

Tel. +41 (0)21 321 0111
Fax. +41 (0)21 321 0169